Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3221-3225

  Hall, Simon J ^a   Sanford, Michael A ^a   Atkinson, Gertrude ^a   Chen, Shu Hsia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; LUNG METASTASIS; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD3; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GANCICLOVIR; GENE THERAPY; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0032146176     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Human Gene Marker/Therapy Clinical Protocols. Hum. Gene Ther., 8: 2301-2334, 1997.
2. Moolten, F. L. Tumor chemosensitivity conferred by inserted thymidine kinase genes: paradigm for a prospective cancer control study. Cancer Res., 46: 5276-5281, 1986.
3. Elshami, A. A., Saavedra, A., Zhang, H., Kucharczuk, J. C., Spray, D. C., Fishman, G. I., Amin, K. M., Kaiser, L. R., and Albelda, S. M. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther., 3: 85-92, 1996.
4. Hamel, W., Magnelli, L., Chiarugi, V. P., and Israel, M. A. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res., 56: 2697-2702, 1996.
5. Barba, D., Hardin, J., Sadelain, M., and Gage, F. H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA, 91: 4348-4352, 1994.
6. Gagandeep, S., Brew, R., Green, B., Christmas, S. E., Klatzmann, D., Poston, G. J., and Kinsella, A. R. Prodrug-activated gene therapy: involvement of an immunological component in the bystander effect. Cancer Gene Ther., 3: 83-88, 1996.
7. Vile, R. G., Castleden, S., Marshall, J., Camplejohn, R., Upton, C., and Chong, H. Generation of an anti-tumor immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a TH1-like profile of intratumoral cytokine expression. Int. J. Cancer, 71: 267-274, 1997.
8. Kianmanesh, A. R., Perrin, H., Panis, Y., Fabre, M., Nagy, H. J., Houssin, D., and Klatzmann, D. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther., 8: 1807-1814, 1997.
9. Whartenby, K. A., Abboud, C. N., Marrogi, A. J., Ramesh, R., and Freeman, S. M. The biology of cancer gene therapy. Lab. Invest., 72: 131-145, 1995.
10. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res., 54: 6228-6234, 1994.
11. Bi, W., Kim, Y. G., Feliciano, E. S., Pavelic, L., Wilson, K. M., Pavelic, Z. P., and Stambrook, P. J. An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther., 4: 246-252, 1997.
12. Iwadate, Y., Namba, H., Tagawa, M., Takeneage, K., Sueyoshi, K., and Sakiyama, S. Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cell by the expression of herpes simplex virus thymidine kinase gene and ganciclovir administration. Oncology. 54: 329-334, 1997.
13. Kuriyama, S., Sakamoto, T., Masui, K., Nakatani, T., Tominga, K., Kikikawa, M., Yoshikawa, M., Ikenaka, K., Fukui, H., and Tsujii, T. Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wildtype hepatocellular tumor. Int. J. Cancer, 71: 470-475, 1997.
14. Yamamoto, S., Suzuki, S., Hoshino, A., Akimoto, M., and Shimada, T. Herpes simplex virus thymidine/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther., 4: 91-96, 1997.
15. Hall, S. J., Mutchnik, S. E., Chen, S-H., Woo, S. L. C., and Thompson, T. C. Adenoviral-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic model of prostate cancer. Int. J. Cancer, 70: 183-187, 1997.
16. Thompson, T. C., Southgate, J., Kitchener, G., and Land, H. Multi-stage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell, 56: 917-930, 1989.
17. Baley, P. A., Yoshida, K., Qian, W., Sehgal, I., and Thompson, T. C. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J. Steroid Biochem. Mol. Biol., 52: 403-413, 1995.
18. Eastham, J. A., Chen, S-H., Sehgal, I., Timme, T. L., Hall, S. J., Woo, S. L. C., and Thompson, T. C. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate models. Hum. Gene Ther., 7: 515-523, 1996.
19. Kawakita, M., Rao, G. S., Ritchey, J. K., Ornstein, D. K., Hudson, M. A., Tartaglia, J., Paoletti, E., Humphrey, P. A., Harmon, T. J., and Ratliff, T. L. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J. Natl. Cancer Inst. (Bethesda), 89: 428-436, 1997.
20. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C., and Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res., 57: 3325-3330, 1997.
21. Chen, S-H., Shine, H. D., Goodman, J. C., Grossman, R. G., and Woo, S. L. C. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated transfer in vivo. Proc. Natl. Acad. Sci. USA, 91: 3054-3057, 1994.
22. Ram, Z., Walbridge, S., Heiss, J. D., Culver, K. W., Blaese, R. M., and Oldfield, E. H. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J. Neurosurg., 80: 535-540, 1994.
23. Elshami, A. A., Kucharczuk, J. C., Sterman, D. H., Smythe, W. R., Hwang, H. C., Amin, K. M., Litzky, L. A., Albelda, S. M., and Kaiser, L. R. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg., 222: 298-310, 1995.
24. Sanda, M. G., Restifo, N. P., Walsh, J. C., Kawakami, Y., Nelson, W. G., Pardoll, D. M., and Simons, J. W. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. (Bethesda), 87: 280-285, 1995.
25. Blades, R. A., Keating, P. J., McWilliam, L. J., George, N. J. R., and Stern, P. L. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology, 46: 681-687, 1995.